Literature DB >> 3115904

Topical mupirocin versus oral erythromycin in the treatment of primary and secondary skin infections.

D Gratton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3115904     DOI： 10.1111/j.1365-4362.1987.tb00600.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  5 in total

Review 1.  Mupirocin in the treatment of impetigo. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1990-03-15       Impact factor: 8.262

2.  Interventions to reduce Staphylococcus aureus in the management of eczema.

Authors:  Susannah Mc George; Sanja Karanovic; David A Harrison; Anjna Rani; Andrew J Birnie; Fiona J Bath-Hextall; Jane C Ravenscroft; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-10-29

Review 3.  Common cutaneous disorders in athletes.

Authors:  R J Conklin
Journal:  Sports Med       Date:  1990-02       Impact factor: 11.136

Review 4.  Interventions for impetigo.

Authors:  Sander Koning; Renske van der Sande; Arianne P Verhagen; Lisette W A van Suijlekom-Smit; Andrew D Morris; Christopher C Butler; Marjolein Berger; Johannes C van der Wouden
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

5.  Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains.

Authors:  R Dagan; Y Bar-David
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.